hpv vaccination
Recently Published Documents





2022 ◽  
Vol 25 ◽  
pp. 101659
Samantha Horn ◽  
Gretchen B. Chapman ◽  
Kriti Chouhan

YMER Digital ◽  
2022 ◽  
Vol 21 (01) ◽  
pp. 277-282
Sreejee Gopalakrishnan ◽  
S Elengkumaran ◽  
S Poojyashree ◽  
Pooja K. N ◽  

Background - The recently developed HPV vaccine is highly effective against the HPV virus. It has met widespread acceptance amongst healthcare and public health professionals. However, there are still social barriers to vaccination that hampers the effects of preventing the disease caused by HPV. The primary goal of this study was to evaluate the survey responses regarding the knowledge, awareness, and vaccination status among dental professionals and students in a local population and to emphasize the relationship between HPV and the increasing incidence of oral and oropharyngeal cancers in the current scenario. Methodology - This study was a prospective analysis of a questionnaire collected from the dentist and dental students at The Faculty of Dental Sciences, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamilnadu, India; regarding their knowledge, awareness, and Human Papilloma Virus (HPV) - vaccination status.Results - 96% of the participants were aware of the HPV and only 4% were unaware of the virus. About 18.7 % of the participants were unaware of the modes of transmission of HPV. Only 66.6 % knew that HPV - 16 and 18 were responsible for Oral and cervical cancers. Conclusion - Understanding the barriers and hesitancy to vaccination is the crucial step to designing strategies that may aid in enhancing the vaccination

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 127
Lawrence B. Afrin ◽  
Tania T. Dempsey ◽  
Leonard B. Weinstock

For nearly a decade, case reports and series have emerged regarding dysautonomias—particularly postural orthostatic tachycardia syndrome (POTS)—presenting soon after vaccination against human papilloma virus (HPV). We too have observed a number of such cases (all following vaccination with the Gardasil product), and have found several to have detectable mast cell activation syndrome (MCAS) as well as histories suggesting that MCAS was likely present long before vaccination. We detail 11 such cases here, posing a hypothesis that HPV vaccination (at least with the Gardasil product) may have triggered or exacerbated MCAS in teenagers previously not recognized to have it. Only recently recognized, MCAS is being increasingly appreciated as a prevalent and chronic multisystem disorder, often emerging early in life and presenting with inflammatory ± allergic phenomena following from known mast cell (MC) mediator effects. There is rising recognition, too, of associations of MCAS with central and peripheral neuropathic disorders, including autonomic disorders such as POTS. Given the recognized potential for many antigens to trigger a major and permanent escalation of baseline MC misbehavior in a given MCAS patient, we hypothesize that in our patients described herein, vaccination with Gardasil may have caused pre-existing (but not yet clinically recognized) MCAS to worsen to a clinically significantly degree, with the emergence of POTS and other issues. The recognition and management of MCAS prior to vaccinations in general may be a strategy worth investigating for reducing adverse events following HPV vaccinations and perhaps even other types of vaccinations.

2022 ◽  
Joemy M. Ramsay ◽  
Heydon K. Kaddas ◽  
Judy Y. Ou ◽  
Deanna Kepka ◽  
Anne C. Kirchhoff

Karolina Sobeczek ◽  
Mariusz Gujski ◽  
Filip Raciborski

Social media platforms are widely used for spreading vaccine-related information. The objectives of this paper are to characterize Polish-language human papillomavirus (HPV) vaccination discourse on Facebook and to trace the possible influence of the COVID-19 pandemic on changes in the HPV vaccination debate. A quantitative and qualitative analysis was carried out based on data collected with a tool for internet monitoring and social media analysis. We found that the discourse about HPV vaccination bearing negative sentiment is centralized. There are leaders whose posts generate the bulk of anti-vaccine traffic and who possess relatively greater capability to influence recipients’ opinions. At the beginning of the COVID-19 pandemic vaccination debate intensified, but there is no unequivocal evidence to suggest that interest in the HPV vaccination topic changed.

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 118
Supattra Rungmaitree ◽  
Charin Thepthai ◽  
Zheng Quan Toh ◽  
Noppasit Musiwiraphat ◽  
Alan Maleesatharn ◽  

HIV-infected patients are at increased risk of human papillomavirus (HPV) acquisition and HPV-associated diseases. This study set out to determine whether a two-dose (2D) HPV vaccination schedule was sufficient in HIV-infected adolescents with immune reconstitution (IR) following antiretroviral treatment. Participants aged 9–15 years who had CD4 cell counts > 500 cells/mm3 and HIV-1 RNA < 40 copies/mL for at least one year were assigned to the 2D schedule, while older participants or those without IR received a three-dose (3D) schedule. Antibodies to HPV-16 and -18 were measured using a pseudovirion-based neutralization assay. A total of 96 subjects were enrolled; 31.3% and 68.7% received the 2D and 3D schedule, respectively. Of these, 66.7% and 57.6% of the 2D and 3D participants, respectively, were male. The seroconversion rates for HPV-16 and HPV-18 were 100% in all cases, except for HPV-18 in males who received the 3D schedule (97.4%). In males, the anti-HPV-16 geometric mean titers (GMTs) were 6859.3 (95% confidence interval, 4394.3–10,707.1) and 7011.1 (4648.8–10,573.9) in the 2D and 3D groups (p = 0.946), respectively, and the anti-HPV-18 GMTs were 2039.3 (1432.2–2903.8) and 2859.8 (1810.0–4518.4) in the 2D and 3D (p = 0.313) groups, respectively. In females, the anti-HPV-16 GMTs were 15,758.7 (8868.0–28,003.4) and 26,241.6 (16,972.7–40,572.3) in the 2D and 3D groups (p = 0.197), respectively, and the anti-HPV-18 GMTs were 5971.4 (3026.8–11,780.6) and 9993.1 (5950.8–16,781.1) in the 2D and 3D groups (p = 0.271), respectively. In summary, a 2D schedule is as immunogenic in young adolescents with IR as a 3D schedule in older subjects and those without IR.

Annalynn M. Galvin ◽  
Ashvita Garg ◽  
Stacey B. Griner ◽  
Jonathan D. Moore ◽  
Erika L. Thompson

Tiziana Cantile ◽  
Stefania Leuci ◽  
Andrea Blasi ◽  
Noemi Coppola ◽  
Roberto Sorrentino ◽  

Background: Pediatric dentists could play a key role in the prevention of human papilloma virus (HPV)-related oropharyngeal cancer (OP-cancer). The aim of this study was to assess knowledge, perception, and attitude on HPV-related OP-cancer, HPV infection, and HPV vaccination among Italian pediatric dentists. Methods: A cross-sectional study was conducted. Pediatric dentists received, by email, a link to participate in the questionnaire online. The questionnaire comprised four parts: (i) demographic information, (ii) knowledge on HPV-related OP-cancer, HPV infection, and HPV vaccine, (iii–iiii) perceptions and attitude on HPV-related OP-cancer, HPV infection, and HPV vaccine. Data were statistically analyzed with Kruskal–Wallis and Mann–Whitney test and Pearson’s chi-square test. Results: A total of 271 pediatric dentists completed the questionnaire. Results showed a good overall knowledge; a positive perception of their role in HPV disease prevention; a good attitude in discussing sensitive topics; a need for acquiring more information about HPV’s connection to cancer, HPV infection, and HPV vaccine. Conclusions: Improving educational training programs, as well as informing about prevention of HPV-related OP-cancer, will place pediatric dentists in the front line of HPV diseases primary prevention.

2022 ◽  
Vol 22 (1) ◽  
Anna Loenenbach ◽  
Michael Pawlita ◽  
Tim Waterboer ◽  
Thomas Harder ◽  
Christina Poethko-Müller ◽  

Abstract Background In Germany, HPV vaccination of adolescent girls was introduced in 2007. Nationally representative data on the distribution of vaccine-relevant HPV types in the pre-vaccination era are, however, only available for the adult population. To obtain data in children and adolescents, we assessed the prevalence and determinants of serological response to 16 different HPV types in a representative sample of 12,257 boys and girls aged 1–17 years living in Germany in 2003–2005. Methods Serum samples were tested for antibodies to nine mucosal and seven cutaneous HPV types. The samples had been collected during the nationally representative German Health Interview and Examination Survey for Children and Adolescents in 2003–2006. We calculated age- and gender-specific HPV seroprevalence. We used multivariable regression models to identify associations between demographic and behavioral characteristics and HPV seropositivity. Results We found low but non-zero seroprevalence for the majority of tested HPV types among children and adolescents in Germany. The overall seroprevalence of HPV-16 was 2.6%, with slightly higher values in adolescents. Seroprevalence of all mucosal types but HPV-6 ranged from 0.6% for HPV-33, to 6.4% for HPV-31 and did not differ by gender. We found high overall seroprevalence for HPV-6 with 24.8%. Cutaneous HPV type seroprevalence ranged from 4.0% for HPV-38 to 31.7% for HPV-1. In the majority of cutaneous types, seroprevalence did not differ between boys and girls, but increased sharply with age, (e.g., HPV-1 from 1.5% in 1–3-years-old to 45.1% in 10–11-years-old). Associations between behavioral factors and type-specific HPV prevalence were determined to be heterogeneous. Conclusions We report the first nationally representative data of naturally acquired HPV antibody reactivity in the pre-HPV-vaccination era among children and adolescents living in Germany. These data can be used as baseline estimates for evaluating the impact of the current HPV vaccination strategy targeting 9–14-years-old boys and girls.

Sign in / Sign up

Export Citation Format

Share Document